enow.com Web Search

  1. Ad

    related to: lipid lowering therapy declined xain3 test

Search results

  1. Results from the WOW.Com Content Network
  2. Lipid-lowering agent - Wikipedia

    en.wikipedia.org/wiki/Lipid-lowering_agent

    Lipid-lowering agents, also sometimes referred to as hypolipidemic agents, cholesterol-lowering drugs, or antihyperlipidemic agents are a diverse group of pharmaceuticals that are used to lower the level of lipids and lipoproteins, such as cholesterol, in the blood (hyperlipidemia). The American Heart Association recommends the descriptor ...

  3. Obicetrapib - Wikipedia

    en.wikipedia.org/wiki/Obicetrapib

    Obicetrapib is an experimental CETP inhibitor that is intended to treat dyslipidemia.In a clinical trial, as an add-on to statins, compared with placebo, it decreased concentrations of LDL-C (by up to 51%), apolipoprotein B (by up to 30%) and non-high-density lipoprotein cholesterol (non-HDL-C) (by up to 44%), and increased HDL-C concentration (by up to 165%).

  4. Why Women are Less Likely to be Prescribed Cholesterol ...

    www.aol.com/why-women-less-likely-prescribed...

    The scientists reported that prescriptions of cholesterol-lowering treatment (statins) were highest immediately following diagnosis and declined over the next three years in all age groups.

  5. Statin - Wikipedia

    en.wikipedia.org/wiki/Statin

    Low-density lipoprotein (LDL) carriers of cholesterol play a key role in the development of atherosclerosis and coronary heart disease via the mechanisms described by the lipid hypothesis. As lipid-lowering medications, statins are effective in lowering LDL cholesterol; they are widely used for primary prevention in people at high risk of ...

  6. Novartis' Cholesterol-Lowering Drug Shows Encouraging Outcome ...

    www.aol.com/novartis-cholesterol-lowering-drug...

    Wednesday, Novartis AG (NYSE:NVS) released topline results from twice-yearly Leqvio (inclisiran) in the Phase 3 V-MONO study, which met its primary endpoints. V-MONO is part of the 60,000-patient ...

  7. Ezetimibe/atorvastatin - Wikipedia

    en.wikipedia.org/wiki/Ezetimibe/atorvastatin

    Ezetimibe/atorvastatin (trade names Liptruzet, Atozet) is a cholesterol lowering combination drug.In the United States, it was approved in May 2013, by the Food and Drug Administration for the treatment of elevated low-density lipoprotein (LDL) in patients with primary or mixed hyperlipidemia as adjunctive therapy to diet. [1]

  8. QRISK - Wikipedia

    en.wikipedia.org/wiki/QRISK

    QRISK3 (the most recent version of QRISK) is a prediction algorithm for cardiovascular disease (CVD) that uses traditional risk factors (age, systolic blood pressure, smoking status and ratio of total serum cholesterol to high-density lipoprotein cholesterol) together with body mass index, ethnicity, measures of deprivation, family history, chronic kidney disease, rheumatoid arthritis, atrial ...

  9. Hypocholesterolemia - Wikipedia

    en.wikipedia.org/wiki/Hypocholesterolemia

    Hypocholesterolemia is the presence of abnormally low (hypo-) levels of cholesterol in the blood (-emia). A defect in the body's production of cholesterol can lead to adverse consequences as well. Cholesterol is an essential component of mammalian cell membranes and is required to establish proper membrane permeability and fluidity.

  1. Ad

    related to: lipid lowering therapy declined xain3 test